Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SMS PharmaceuticalsBOM:532815 +10.77%74 5-Year Yield-on-Cost % is 0.09 as of Sep. 14, 2026, which is 63% below its 10-year median of 0.24. GuruFocus rates BOM:532815 with a GF Score™ of 74/100 and a GF Value™ of ₹284.35 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 507 Drug Manufacturers companies, SMS Pharmaceuticals ranks worse than 96.84% on this metric.
SMS Pharmaceuticals's yield on cost for the quarter that ended in Jun. 2026 was 0.09.
The historical rank and industry rank for SMS Pharmaceuticals's 5-Year Yield-on-Cost % or its related term are showing as below:
BOM:532815'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.08 Med: 0.24 Max: 1.79
Current: 0.09
During the past 13 years, SMS Pharmaceuticals's highest Yield on Cost was 1.79. The lowest was 0.08. And the median was 0.24.
BOM:532815's 5-Year Yield-on-Cost % is ranked worse than 96.84% of 507
companies
in the Drug Manufacturers industry
Industry Median: 2.41
vs BOM:532815: 0.09
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
SMS Pharmaceuticals 5-Year Yield-on-Cost % Related Terms
BOM:532815 vs LLY, JNJ, ABBV: 5-Year Yield-on-Cost % Comparison
For the Drug Manufacturers - General subindustry, SMS Pharmaceuticals's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SMS Pharmaceuticals 5-Year Yield-on-Cost % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, SMS Pharmaceuticals's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where SMS Pharmaceuticals's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
SMS Pharmaceuticals (BOM:532815) has a 5-Year Yield-on-Cost % of 0.09 as of Sep. 14, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on SMS Pharmaceuticals and its competitors. This is 63% below median its historical median of 0.24. Over the past decade, SMS Pharmaceuticals' 5-Year Yield-on-Cost % has ranged from 0.08 to 1.79. According to the industry distribution chart, SMS Pharmaceuticals ranks #491 out of 507 companies in the Drug Manufacturers industry, placing it in the top 96.8%.
Is SMS Pharmaceuticals' 5-Year Yield-on-Cost % too high?
SMS Pharmaceuticals' current 5-Year Yield-on-Cost % of 0.09 is 63% below median its 10-year median of 0.24. Over the past 10 years, this metric has ranged from a low of 0.08 to a high of 1.79. The Drug Manufacturers industry median 5-Year Yield-on-Cost % is 2.41. SMS Pharmaceuticals' value of 0.09 is 96.3% below this industry median. Based on the distribution chart, SMS Pharmaceuticals ranks #491 out of 507 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, SMS Pharmaceuticals has a GF Score™ of 74/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does SMS Pharmaceuticals' 5-Year Yield-on-Cost % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, SMS Pharmaceuticals ranks #491 out of 507 companies for 5-Year Yield-on-Cost %. This places SMS Pharmaceuticals in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.41. SMS Pharmaceuticals' value of 0.09 is 96.3% below this benchmark. Historically, SMS Pharmaceuticals' own 5-Year Yield-on-Cost % has ranged from 0.08 to 1.79 over the past decade. While the company's 10-year median is 0.24 vs. the industry median of 2.41, SMS Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.41, based on 507 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SMS Pharmaceuticals's current 5-Year Yield-on-Cost % of 0.09 is 96.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on SMS Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SMS Pharmaceuticals's current 5-Year Yield-on-Cost % is 0.09, which is 63% below median its own 10-year median of 0.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SMS Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, SMS Pharmaceuticals (BOM:532815) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹284.35, compared to a current price of ₹464.30 — trading 63.3% above its estimated fair value. The current 5-Year Yield-on-Cost % is 0.09, which is 63% below median its 10-year median of 0.24 and 96.3% below the Drug Manufacturers industry median of 2.41. SMS Pharmaceuticals' overall GF Score™ is 74/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For SMS Pharmaceuticals (BOM:532815), the current 5-Year Yield-on-Cost % is 0.09 as of Sep. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SMS Pharmaceuticals (BOM:532815) Overvalued in 2026?
Based on GuruFocus' analysis, SMS Pharmaceuticals stock appears to be overvalued.
The current stock price of ₹464.30 is trading 63.3% above its estimated GF Value™ of ₹284.35.
GuruFocus considers SMS Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for BOM:532815:
5-Year Yield-on-Cost %: 0.09 (63% below median its 10-year median of 0.24)
GF Value™: ₹284.35 vs. price of ₹464.30 (63.3% above fair value)
Industry Position: 96.3% below the Drug Manufacturers median (#491 of 507)
No single metric tells the full story. See the BOM:532815 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SMS Pharmaceuticals Ltd is a drug manufacturing company. It is engaged in the business of manufacturing Active Pharma Ingredients and their intermediates. Its product portfolio includes drugs for anti-ulcer, anti-fungal, anti-migraine, anti-diabetic, erectile dysfunction, anti-viral, and other conditions.
74GF Score
Get the complete analysis for BOM:532815
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:532815 has been successfully added to your 
